37 results about "Colonic adenocarcinoma" patented technology

The invention discloses a serum miRNAs specific expression profile for early colonic adenocarcinoma and rectal adenocarcinoma, which is formed by up-regulated expressed miR-19a-3p, miR-92a-3p and miR223-3p and down-regulated expressed miR422a. A reverse transcription primer and a detection primer, which are shown as SEQ ID NO: 1-9, of the miRNAs are specifically expressed in the serum miRNAs specific expression profile for the early colonic adenocarcinoma and rectal adenocarcinoma. The invention also provides a serum miRNAs disgnosis model for the early colonic adenocarcinoma and rectal adenocarcinoma, the following formula of logit(P=CAC)=0.4424-0.0092*(miR-19a-3p)-0.0368*(miR-92a-3p)-0.0517*(miR-223-3p)+0.2439*(miR-422a) is used for calculation and for the diagnosis on the early colonic adenocarcinoma and rectal adenocarcinoma, the diagnosis efficiency of the serum miRNAs model on the colonic adenocarcinoma and rectal adenocarcinoma is higher and is higher than that of the traditional tumor marker CEA through ROC (Receiver Operating Characteristic) curve analysis, and the model can used for the diagnosis on the early colonic adenocarcinoma and rectal adenocarcinoma patient (TNM I / II period).

The invention discloses a gene expression classifier for predicting colonic adenocarcinoma prognosis, and an establishment method for the classifier. The establishment method comprises a data training stage and a verification stage. The training stage comprises a first stage and a second stage; in the first stage, a gene expression classifier prototype capable of predicting the colonic adenocarcinoma prognosis is established by using a supervised machine learning method; and in the second stage, the gene expression classifier for predicting the colonic adenocarcinoma prognosis is obtained by further using the machine learning method. The gene expression classifier can predict not only prognosis of patients suffering from colonic adenocarcinoma but also prognosis of patients suffering from kidney cancers, lung squamous cancers, eye ground and skin melanin tumors, brain cancers and pancreatic cancers, thereby providing accurate judgment criteria for postoperative adjuvant treatment of the patients suffering from the cancers.

The invention relates to a new application of furanodiene in pharmacy field, in particular to the application of the furanodiene in the preparation of medicines for treating the various malignant tumor diseases such as oophoroma, cervical carcinoma, gastric cancer, liver cancer, leucocythemia, lung cancer, oral carcinoma (epidermoid carcinoma), rectal adenocarcinoma, mammary cancer, malignant melanoma, colonic adenocarcinoma, nasopharyngeal carcinoma, carcinoma of prostate, etc. The invention also relates to the application of the furanodiene in the preparation of drugs for treating the diseases caused by herpesvirus, influenza virus and hepatitis B virus.

The invention discloses a primer capable of detecting the methylation of a promoter of a gene related to colonic adenocarcinoma. The primer which is used for detecting the methylation of a DNA (Deoxyribonucleic Acid) to be detected provided by the invention consists of a primer pair A, a primer pair B, a primer pair C, a primer pair D, a primer pair E and a primer pair F, wherein the primer pair A consists of a primer 1 and a primer 2, the primer pair B consists of a primer 3 and a primer 4, the primer pair C consists of a primer 5 and a primer 6, the primer pair D consists of a primer 7 and a primer 8, the primer pair E consists of a primer 9 and a primer 10, the primer pair F consists of a primer 11 and a primer 12, and nucleotide sequences of the primers 1-12 are sequences 1-12 in the sequence table. When the primer capable of detecting the methylation of the DNA is adopted, a Tm value of the primer can be controlled at 60 DEG C, specificity and amplification efficiency of a PCR (Polymerase Chain Reaction) product are ensured, and methylated state of samples of colonic adenocarcinoma and adenoma can be efficiently detected.

The invention discloses a food allergen dynamic digestion model and an in-vitro simulation evaluation method. The method mainly comprises the steps of establishing an allergen dynamic digestion modeland an in-vitro simulation evaluation method, simulating a biochemical reaction condition of the stomach and duodenum of a human body through a digestive system simulation device, providing a method for constructing an allergen in-vitro simulated dynamic digestion experiment in the simulated evaluation method, constructing a Caco-2 (human cloned colonic adenocarcinoma cells) small intestine epithelial cell model to simulate small intestine absorption and transport effects, and constructing a KU812 (human peripheral blood basophilic leukemia cells) cell model to evaluate the ability of mast cell degranulation induced by food allergen digestion and transport products. The method of the invention is suitable for evaluating the digestion and sensitization of a purified food allergen or an allergen extracting solution containing a complex food matrix.

The invention relates to a nano-material cell-based biosensor, a preparation method thereof and a new method using the nano-material cell-based biosensor to evaluate the antioxidant activity of antioxidant polypeptides and relates to the field of antioxidant capacity measuring. Colonic adenocarcinoma cells are used as the sensing elements to build a cell gel three-dimensional network structure, and the cell gel three-dimensional network structure is combined with nano-material modification electrodes to evaluate the antioxidant activity of the polypeptides. The method using the cells to simulate electrochemical signals so as to evaluate the antioxidant activity of the polypeptides is novel and convenient in detection and has high practicality in the comprehensive evaluation of the cell protection effect of antioxidant substances.

The present invention relates to one kind of mixture solution containing conjugate of transferrin and quercetin. The mixture solution is prepared through dissolving transferrin and quercetin separately in pH 6.8-7.8 phosphate buffer solution, mixing transferrin solution and quercetin solution in the molar ratio between transferrin and quercetin of 1 to 4, diluting the mixture solution with phosphate buffer solution to quercetin concentration of 40 micromole, shaking and standing to obtain the mixture solution containing conjugate of transferrin and quercetin. The mixture solution has conjugated transferrin and quercetin in phosphate buffer solution of proper pH condition, raised cytotoxic effect on tumor of quercetin, and raised targeting effect of small medicine molecule on tumor cell, and may be used in preparing medicine for treating colonic adenocarcinoma.

The present invention provides copper complexes of a series of amino acids and phenanthroline or a phenanthroline derivative and a preparation method and application thereof, and the copper complexes are respectively prepared by bonding the amino acids, the phenanthroline or the phenanthroline derivative, and other small molecule ligand with copper ions. The preparation method of the copper complexes is as follows: the series of amino acids, the phenanthroline or the phenanthroline derivative, a copper salt and the small molecule ligand are stirred in an organic solvent for reaction to obtain the complexes. The synthesis raw materials of the copper complexes are easily-available and low in cost, the products are precipitated in crystalline forms, the purity is high, the yield is high, the copper complexes can be stable in the natural state, and by introduction of the amino acids, the copper complexes have good water-soluble and fat soluble and biological-fusion properties. In addition, the complexes show excellent inhibition effects on a plurality of kinds of cancer cells of lung cancer, gastric cancer, liver cancer, colonic adenocarcinoma, leukemia, cancer and the like, and are broad in spectrum of action and wide in range of application.

The invention relates to a method for establishing a model of fluorescence orthotopic transplantation of subcutaneous metastasis organ cancers, which is characterized in that human colon adenocarcinoma cell strains or cancer cell strain green fluorescent proteins (GFP) of corresponding organs are selected; GFP plasmids carry out transfection on cancer cell strains of the organs via retrovirus pLPCX so that the cancer cell strains of the organs contain GFP expression plasmids; a GFP gene is connected with a pLPCX vector via a T4 ligase; a GFP-pLPCX vector is transfected to a PT67 package cell to obtain a Lovo cell; nude mice are selected and subjected to subcutaneous inoculation with Lovo cell suspension; tumors can be formed in about 4 weeks; orthotopic transplantation is carried out after green fluorescence is observed; a cut is opened on the skin and peritoneum; about 1cm cecum of the nude mice is taken out of the peritoneum; the gap between the cecum and the peritoneum is sutured and the cecum is transferred subcutaneously; the cut cecum is subjected to serosa; two fluorescence-carrying tumors with diameter of about 1mm are transplanted to the cecum via the suture and the skin is closed.

The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.

The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.

The invention discloses a copper complex of a phenanthroline derivative, a preparation method and application of the copper complex. The copper complex of the phenanthroline derivative comprises one or multiple substitutive derivatives of 1,10-phenanthroline, acid radicals and / or small organic molecules (comprising solvent molecules) and copper ions. The preparation method of the complex comprises the steps of stirring the one or multiple substitutive derivatives of 1,10-phenanthroline and copper salt in a solvent and reacting to obtain the complex. The copper complex has the beneficial effects that the raw materials for synthesizing the complex are easily available and low in cost, and the product is separated out in a crystal manner and has high purity and high yield; the copper complex can exist stably in a natural state and has good water solubility and lipid solubility; in addition, the copper complex has an excellent inhibiting effect on multiple cancer cells such as lung cancer cells, gastric cancer cells, liver cancer cells, colonic adenocarcinoma cells, leukemia cells, nasopharynx cancer cells and the like, a wide action spectrum and a wide application range.

The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.

The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.

The invention relates to the technical field of microorganisms, and discloses a strain of marine aspergillus versicolor and an isolated culture method and application thereof, wherein the preservation number of the marine aspergillus versicolor is GDMCC No: 61106, and the marine aspergillus versicolor is classified and named as Aspergillus versicolor SCAU141. The marine aspergillus versicolor separation culture method is easy to operate, the strain is convenient to obtain, and the marine aspergillus versicolor has the capability of preparing the exopolysaccharide; the method for preparing the exopolysaccharide by utilizing the marine aspergillus versicolor is simple and mild in condition; the prepared exopolysaccharide has remarkable anti-cancer activity, and has a good inhibition effect on the growth of three common cancer cells such as lung cancer, liver cancer and colonic adenocarcinoma; in addition, the prepared exopolysaccharide also has good bacteriostatic activity, and especially has a remarkable inhibition effect on the growth of nocardia. Therefore, the exopolysaccharide prepared in the invention has good application potential and popularization prospect as a microecological preparation capable of resisting cancer and inhibiting bacteria, and can provide scientific research reference basis for research and development of environment-friendly marine biological preparations.

The invention discloses a method for evaluating the immune regulation effect of lactobacillus acidophilus, and relates to a method for evaluating the immune regulation effect. The method comprises the following steps of: 1, culturing the lactobacillus acidophilus to be evaluated to a post-logarithmic growth phase to prepare bacterial suspension; 2, incubating human colonic adenocarcinoma cells Caco-2 in a polarized state and the bacterial suspension together; 3, extracting total RNA and protein from the incubated human colonic adenocarcinoma cells Caco-2 by a trizol method; and 4, detecting and comparing the expression level of an immune regulation related gene in the total RNA and the protein respectively by a real-time RT-PCR method and western blot method. The method can more objectively evaluate possible adverse inflammatory reaction and the like of the lactobacillus acidophilus on a host to eliminate potential pathogenic risk by detecting the immune regulation related gene.

The invention relates to a molybdenum compound [MoO2Cl2(H2O)2][15C5] of 15-crown-5 and molybdenum, preparation method and application thereof. The molybdenum compound provided by the invention can prevent and inhibit the formation and growth of cancers and tumors, and can be used for preparation of drugs preventing and treating cancer and tumor diseases. Synthesis of the compound drug provided by the invention has the characteristics of easily available raw materials and low cost, the product precipitates out in the form of crystals, has high purity and yield, can stably exist under natural state, has good water solubility and lipid solubility, and presents excellent inhibition effect on A-549 (lung cancer), Bel-7402 (liver cancer), and HCT (colonic adenocarcinoma).

The invention relates to the field of medicinal chemistry, and in particular, relates to an application of a brefeldin A ester derivative in the aspect of inhibiting tumor proliferation activity; the brefeldin A ester derivative can be used for preventing or treating hyperproliferative diseases, and the structure of the brefeldin A ester derivative is represented by a formula (I). Hyperproliferative diseases comprise liver cancer, leukemia, breast cancer, colonic adenocarcinoma, gastric cancer, lung cancer, Bartter's esophagus cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymph cancer, kidney cancer, brain cancer, nerve cancer, nasopharynx cancer, oral cancer and colorectal cancer, so that the brefeldin A ester derivative has the potential of being developed into a novel antitumor drug.

The invention discloses a serum miRNAs specific expression profile for early colonic adenocarcinoma and rectal adenocarcinoma, which is formed by up-regulated expressed miR-19a-3p, miR-92a-3p and miR223-3p and down-regulated expressed miR422a. A reverse transcription primer and a detection primer, which are shown as SEQ ID NO: 1-9, of the miRNAs are specifically expressed in the serum miRNAs specific expression profile for the early colonic adenocarcinoma and rectal adenocarcinoma. The invention also provides a serum miRNAs disgnosis model for the early colonic adenocarcinoma and rectal adenocarcinoma, the following formula of logit(P=CAC)=0.4424-0.0092*(miR-19a-3p)-0.0368*(miR-92a-3p)-0.0517*(miR-223-3p)+0.2439*(miR-422a) is used for calculation and for the diagnosis on the early colonic adenocarcinoma and rectal adenocarcinoma, the diagnosis efficiency of the serum miRNAs model on the colonic adenocarcinoma and rectal adenocarcinoma is higher and is higher than that of the traditional tumor marker CEA through ROC (Receiver Operating Characteristic) curve analysis, and the model can used for the diagnosis on the early colonic adenocarcinoma and rectal adenocarcinoma patient (TNM I / II period).

The invention provides a prognostic marker and prognostic risk assessment model for metastatic colon adenocarcinoma and application of the prognostic marker and the prognostic risk assessment model. The prognostic marker comprises a combination of any one or at least two of prognostic related genes LEP, DLX2, CLSTN2 or REG3A. Meanwhile, the invention further provides three potential treatment drugs for the metastatic colon adenocarcinoma, namely ajmaline, TTNPB and dydrogesterone. The prognostic marker provided by the invention is remarkably related with the survival of a colon adenocarcinoma(COAD) patient, and the risk assessment model constructed by utilizing the prognostic marker can carry out risk assessment and survival analysis on patients, and the accuracy is relatively high.

The invention relates to a colonic adenocarcinoma susceptibility prediction kit which comprises the following components: an STR-1 primer, an STR-2 primer, an STR-3 primer, an STR-4 primer, an STR-5 primer and an STR-6 primer, and further can comprise a PCR amplification reaction solution, an LIZ-500 molecular weight internal standard and deionized formamide. The colonic adenocarcinoma susceptibility prediction kit provided by the invention can be used for diagnosing colonic adenocarcinoma and predicting susceptibility. The invention also provides a colonic adenocarcinoma susceptibility prediction system.

The invention relates to the field of medicinal chemistry, and in particular, relates to an application of a brefeldin A derivative represented by a formula (I) in the aspect of inhibiting tumor proliferation activity. The novel compound has outstanding effects in preventing or treating hyperproliferative diseases including liver cancer, leukemia, breast cancer, colonic adenocarcinoma, gastric cancer, lung cancer, Bartter's esophagus cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymph cancer, kidney cancer, brain cancer, nerve cancer, nasopharynx cancer, oral cancer and colorectal cancer, and has the potential of being developed into a novel antitumor drug.

The invention discloses a primer capable of detecting the methylation of a promoter of a gene related to colonic adenocarcinoma. The primer which is used for detecting the methylation of a DNA (Deoxyribonucleic Acid) to be detected provided by the invention consists of a primer pair A, a primer pair B, a primer pair C, a primer pair D, a primer pair E and a primer pair F, wherein the primer pair A consists of a primer 1 and a primer 2, the primer pair B consists of a primer 3 and a primer 4, the primer pair C consists of a primer 5 and a primer 6, the primer pair D consists of a primer 7 and a primer 8, the primer pair E consists of a primer 9 and a primer 10, the primer pair F consists of a primer 11 and a primer 12, and nucleotide sequences of the primers 1-12 are sequences 1-12 in the sequence table. When the primer capable of detecting the methylation of the DNA is adopted, a Tm value of the primer can be controlled at 60 DEG C, specificity and amplification efficiency of a PCR (Polymerase Chain Reaction) product are ensured, and methylated state of samples of colonic adenocarcinoma and adenoma can be efficiently detected.

The invention provides a method for establishing a tumor cachexia model of deficiency syndrome. The method comprises, at the same time, adopting the three-factor induction method of bitter cold diarrhea, hunger and fullness, and exhausted exercise to establish a deficiency syndrome mouse model, and inducing it for 7-15 days; inoculating the obtained deficiency syndrome mice with C26 colon adenocarcinoma cells to obtain deficiency syndrome Tumor cachexia model: After inoculation, the two-factor induction method of bitter cold diarrhea and abnormal hunger and fullness is adopted at the same time, and the induction is continued for 15‑18 days. Among them, body weight, thymus weight, spleen weight, and gastrin content were selected as observation indicators for deficiency syndrome. The animal model established by the above method can be used to study deficiency syndrome tumor cachexia or to screen drugs for treating deficiency syndrome tumor cachexia.

The chemotherapeutic drug is cisplatin. The invention discloses application of arginine in preparation of an anticarcinogen as a synergist of a chemotherapeutic drug. An in-vitro cell experiment result shows that when the arginine and the cisplatin are used jointly, an inhibiting action on a human colonic adenocarcinoma cell HT29 can be improved remarkably, and a synergistic action can be achieved. Under the condition of the same inhibiting effect, the dosage of the cisplatin is lowered, and thus, potential adverse reactions of the cisplatin can be reduced effectively.

The invention belongs to the technical field of medicine and relates to styrene-acrylic sucrose ester glycoside compounds of cherries and a preparation method thereof. Five novel styrene-acrylic sucrose ester glycoside compounds with anti-tumor activity comprise 3,-p-coumaroyl-1,4,6'-triacetyl sucrose, 3,-p-coumaroyl-2',3',6'-triacetyl sucrose, 3,-p-coumaroyl-1,4',6'-triacetyl sucrose, 3,-p-coumaroyl -3',4',6'-triacetyl sucrose and 3-ferulic acyl-1,2',6'-triacetyl sucrose; and the five compounds have good inhibition effects on the MCF-7 human breast cancer cell line, A-549 human non-small-cell lung cancer cells, the HeLa cervical cancer cell line and HT-29 human colonic adenocarcinoma cell line, and are expected to be applied to preparation of anti-tumor medicines.